It really is a momentous occasion when one of the Tear Film and Ocular Surface Society’s (TFOS’) global consensus reports is published: a culmination of years of work for many people, as they translat
Identification of microplastics in human tear fluid and meibum: Implications for dry eye disease pathogenesis Jingyi Wang et al J Hazard Mater. 2025 Feb;489:137635 Review: This cross-sectional, la
The 2007 Tear Film & Ocular Surface Society Dry Eye Workshop (TFOS DEWS)1 marked a major milestone in standardising the understanding and management of dry eye disease (DED). A decade later, TFOS DEWS II (2017)2 expanded on this foundation, supported by widespread global research. Now, TFOS DEWS
Building on the momentum gained from the recent success of our second public education and networking event held earlier this year, Dry Eye Association NZ seeks to further establish and expand its pla
Artificial intelligence (AI) is on the verge of reshaping contact lens (CL) practices, being incorporated into tools that enhance fitting accuracy, streamline workflows and personalise treatment, acco
For the people living with dry eye and their supporters who gathered on a chilly autumn morning in Auckland at the Dry Eye Association NZ’s (DEANZ) second public education and networking meeting, it was more than just an event – it was a chance to be seen and heard.
One year after launching its intense pulsed light (IPL) pilot, Specsavers Australia is rolling out the service to two more stores, taking the total to 11, with more expected to follow. IPL treatment
Researchers in Australia found successful dry eye disease (DED) treatment with ocular lubricants also diminished migraine severity in susceptible patients.
Creating more effective and equitable systems by embracing patient and public involvement in clinical care, education and research
A serendipitous moment in the Department of Ophthalmology at the University of Auckland led to a dream gift for BOptom graduate-turned-researcher Jordan Cooper. Concerned about funding Cooper’s PhD, his supervisor and mentor, Professor Jennifer Craig, head of the Ocular Surface Laboratory, shared he
Patients with dry eye disease (DED) reported symptom relief in as early as five and 60 minutes after a single administration of Bausch + Lomb’s new ophthalmic solution Miebo, with relief maintained th
A new study¹ published in The Ocular Surface journal has found a strong need for individualised treatment strategies for patients suffering from dry eye disease (DED). Using real-world data from the
